Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.42 |
| ▸ | RAF1 | P04049 | 6/20 | 0.42 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | STAMBP | O95630 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999700 | 0.92 | SLC34A2 (0.46) | BRAFRAF1SLC34A2KDM1AHDAC1 | |
| SCHEMBL16804643 | 0.91 | BRAF (0.43) | BRAFRAF1SLC34A2KDM1AHDAC1 | |
| SCHEMBL15432532 | 0.87 | SLC34A2 (0.43) | BRAFRAF1SLC34A2KDM1AHDAC1 | |
| SCHEMBL46676 | 0.86 | SLC34A2 (0.43) | BRAFRAF1SLC34A2KDM1AHDAC1 | |
| SCHEMBL18059179 | 0.85 | IRAK4 (0.40) | BRAFRAF1HDAC1CSF1R | |
| SCHEMBL46729 | 0.85 | SLC34A2 (0.46) | BRAFRAF1SLC34A2KDM4EGAA | |
| SCHEMBL39840 | 0.85 | SLC34A2 (0.45) | BRAFRAF1SLC34A2KDM4EGAA | |
| SCHEMBL40137 | 0.85 | CHRM3 (0.43) | BRAFRAF1SLC34A2KDM4EHRH4 | |
| SCHEMBL40133 | 0.84 | SLC34A2 (0.41) | BRAFRAF1SLC34A2KDM1AHDAC1 | |
| SCHEMBL46466 | 0.84 | SLC34A2 (0.41) | BRAFRAF1SLC34A2KDM4EHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | BRAF 3436/4885RAF1 3203/4885SLC34A2 1/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | BRAF 3436/4885RAF1 3203/4885SLC34A2 1/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | BRAF 3909/4885RAF1 3987/4885SLC34A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.